title: Evaluation of neurotoxicity induced by paclitaxel second-line chemotherapy.
abstract: The most important cytotoxic drugs for the treatment of ovarian cancer, platinum compounds and paclitaxel, are known to induce neurotoxicity, which is dose limiting when higher paclitaxel doses are used or platinum-pretreated patients are treated. The absolute dose of paclitaxel per course has been demonstrated to be an important risk factor for the development of neurotoxicity. The role of cumulative dose, treatment duration and infusion schedule as additional risk factors are still in debate, and are therefore evaluated in this study. This study evaluates paclitaxel induced neurotoxicity in 38 patients, most of whom had already received platinum treatment, receiving either 135 or 175 mg/m2 as 3-h or 24-h infusion. Patients were compared with an age-matched control group. A detailed questionnaire and neurophysiological measurements including vibration perception threshold were used. Overall, the majority of patients (76%) developed some degree of neurotoxicity, but symptoms were usually mild or moderate with no grade 3/4 neurotoxicity observed. Age has been demonstrated to be an important risk factor for the development of neurotoxicity. Furthermore, the higher dose per course showed a significant impact on neurotoxicity, while the different infusion schedules were of minor importance. Vibration threshold perception, 2-point discrimination, a walking-the-line test, and reports of paresthesias were shown to be the most sensitive and useful parameters for neurotoxicity evaluation. Neurotoxicity is a common adverse event during paclitaxel chemotherapy in platinum-pretreated patients. A clinically useful test panel composed of a detailed history and the above three easily performed neurophysiological evaluations should be incorporated into future studies evaluating new drugs, treatment modifications, new combinations, and potential modulators of chemotherapy-induced neurotoxicity.
authors.affiliation: Department of Gynecology and gynecologic Oncology, Wiesbaden, Germany.
authors.forename: A
authors.initials: A
authors.lastname: du Bois
authors.forename: M
authors.initials: M
authors.lastname: Schlaich
authors.forename: H J
authors.initials: HJ
authors.lastname: Lück
authors.forename: A
authors.initials: A
authors.lastname: Mollenkopf
authors.forename: U
authors.initials: U
authors.lastname: Wechsel
authors.forename: M
authors.initials: M
authors.lastname: Rauchholz
authors.forename: T
authors.initials: T
authors.lastname: Bauknecht
authors.forename: H G
authors.initials: HG
authors.lastname: Meerpohl
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D016022:Case-Control Studies; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000009:adverse effects*; D010292:Paresthesia / Q000139:chemically induced*; D011597:Psychomotor Performance / Q000187:drug effects*; D012026:Reflex, Stretch / Q000187:drug effects; D011795:Surveys and Questionnaires
chemical_list: D000970:Antineoplastic Agents; D017239:Paclitaxel